Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma (NYSE American: CANF) announced positive results from a clinical study in dogs with osteoarthritis conducted by its partner Vetbiolix. The study found that Piclidenoson significantly improved clinical status and reduced pain in canine patients. The study, which utilized a 90-day treatment period with doses of 100 μg/kg and 500 μg/kg administered twice daily, met both primary and secondary objectives. The primary objective was assessed using the Liverpool OsteoArthritis in Dogs (LOAD) questionnaire, while secondary objectives included pain assessments through Visual Analog Scale (VAS) and Numerical Rating Score (NRS). The 500 μg/kg dose showed the most significant improvement. Vetbiolix may now enter a full in-license agreement with Can-Fite, including upfront and milestone payments, as well as royalties upon regulatory approval. The canine osteoarthritis market is projected to reach $3 billion by 2028.
Can-Fite BioPharma (NYSE American: CANF) has announced breakthrough findings regarding Namodenoson, a drug demonstrating significant anti-cancer and protective effects in the liver. These effects are attributed to the signaling protein adiponectin, which has key roles in anti-inflammatory, anti-cancer, metabolic, and insulin resistance regulation. Namodenoson has been shown to increase adiponectin production in both pre-clinical studies and human trials. The data will be presented at the 20th Annual Congress of International Drug Discovery Science & Technology in China, from September 12-14, 2024. Namodenoson is currently being evaluated in a Phase III study for advanced liver cancer and a Phase IIb study for MASH.
Can-Fite BioPharma (NYSE American: CANF) announced IRB approval from Rabin Medical Center for a Phase IIa study on Namodenoson for pancreatic cancer treatment. The open-label trial will enroll around 20 patients whose disease has advanced despite first-line treatment. The study will evaluate safety and clinical activity, with patients receiving 25 mg of Namodenoson twice daily. Previous studies showed promising results, encouraging this new trial. The study protocol CF102-222PC has been submitted to the Ministry of Health. Key endpoints include safety, Objective Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS).
Can-Fite BioPharma has provided an update on the pivotal Phase 3 study for Namodenoson, its lead drug candidate for advanced liver cancer. The study involves 31 medical centers across Europe, Israel, and the US, with Namodenoson holding Orphan Drug and Fast Track status from the FDA.
The compassionate use program is ongoing in Israel and Romania. Previous Phase 2 results showed that Namodenoson prolonged survival and improved quality of life in patients, with some achieving long-term complete responses.
The Phase 3 LIVERATION trial will enroll 450 patients with advanced liver cancer and Child Pugh B7 cirrhosis, comparing Namodenoson to a placebo. The trial's primary endpoint is overall survival, with interim analysis by an Independent Data Monitoring Committee after 50% enrollment.
Liver cancer causes over 700,000 deaths annually, with the HCC treatment market projected to reach $3.8 billion by 2027.
Can-Fite BioPharma announced that the International Journal of Molecular Sciences published a review highlighting the positive effects of its drugs, piclidenoson and namodenoson, on heart diseases. The review, based on over 50 publications, showed that these drugs improved outcomes in pre-clinical studies, such as reducing infarct size and protecting against ischemic injury. Dr. Pnina Fishman noted the drugs' cardio-protective potential and their good safety profile observed in over 1600 patients. Can-Fite is also advancing clinical studies in psoriasis, liver cancer, MASH, and pancreatic cancer.
Can-Fite BioPharma announced that its VP of Business Development, Dr. Sari Fishman, will engage in 23 partnering meetings at the Bio International Convention 2024 in San Diego from June 3-6. These meetings aim to explore potential collaborations with biotech and pharma companies. Can-Fite has existing out-licensing and distribution agreements with seven pharma companies across North America, Europe, and Asia. The company is currently developing two small molecule drugs: Piclidenoson for psoriasis (Phase 3) and Namodenoson for advanced liver cancer (Phase 3), pancreatic cancer (Phase 2a), and NASH (Phase 2b).
Can-Fite BioPharma (NYSE American: CANF; TASE: CANF), a biotechnology firm focused on small molecule drugs for oncological and inflammatory diseases, invites investors to a webinar on June 6, 2024, at 4:15 p.m. ET.
Hosted by RedChip Companies, the event will feature CEO Motti Farbstein and Executive Chairperson/Chief Scientific Officer Pnina Fishman, PhD. They will discuss the company's current development pipeline and upcoming milestones.
Investors can register for the free webinar and pre-submit questions at the provided link.
Can-Fite BioPharma held a conference for 75 oncologists and coordinators to accelerate patient enrollment for the pivotal Phase 3 advanced liver cancer study. The study aims to evaluate Namodenoson as a 2nd or 3rd line treatment for CPB7 patients with HCC. The drug has Orphan Drug status and Fast Track Status with the FDA for HCC treatment. The market for HCC treatments is projected to reach $6.1 billion by 2027.
RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.
Can-Fite BioPharma has received FDA clearance for its small molecule drug, Namodenoson, to treat MASH patients in a Phase IIb study. The drug targets the A3 adenosine receptor in liver cells, showing promise in reducing hepatic steatosis, inflammation, and fibrosis. The Phase IIb trial aims to evaluate Namodenoson's efficacy in 140 MASH patients, with enrollment now open in the US.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
